Background and Purpose
Asthma is a condition that causes inflammation in the lungs. The main treatment used to reduce this inflammation is inhaled corticosteroids (ICS). These medications help both the large and small airways.
Study Overview
This study included 30 asthma patients who were on step 3 treatment as per GINA guidelines. They were divided into two groups to compare two types of inhaled medications: beclomethasone/formoterol (BDP/F) and budesonide/formoterol (BUD/F). Each group used one type of medication for 6 weeks, then switched to the other type after a 4-week break. The effectiveness was measured using various tests including the Asthma Control Test (ACT) and lung function tests.
Results
Out of 30, 24 patients finished the study. The results for lung function improvement (FEF25-75% pred) were similar for both BDP/F and BUD/F. There was no significant difference in overall asthma control or quality of life between both medications. However, patients who showed a positive response to a specific test (methacholine bronchial provocation) had better ACT scores with BDP/F compared to BUD/F.
Conclusions
The study found that using extrafine ICS did not show clear benefits over non-extrafine ICS for controlling asthma symptoms. This indicates that other factors may play a role in how effective the treatments are.
Opportunities for Improvement
Based on the trial results, there are a few steps that clinics and patients can take:
- Define Measurable Outcomes: Set specific goals for asthma control and quality of life improvements.
- Select Appropriate AI Tools: Choose AI solutions that can help monitor and manage asthma treatment effectively.
- Implement Gradually: Start with a small project to test AI solutions and track their effectiveness in real-life scenarios.
Contact Us
For more information on AI solutions in asthma management, reach out to us via:
- Telegram: https://t.me/itinai
- X: https://x.com/vlruso
- LinkedIn: https://www.linkedin.com/company/itinai/
